LPIN1 and prostate cancer: The overexpression of lipin-1 was confirmed in situ in prostate cancer and in other cancer types, notably in triple negative breast cancer (TNBC) and in lung adenocarcinomas, where it is associated with poor prognosis [37,38,39].